{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-084617","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2026-07-17T20:05:26+00:00","discovered_at":"2026-07-17T20:06:00.322650+00:00","generated_at":"2026-07-17T20:06:05.300666+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"TransCode Therapeutics amends Series C Preferred beneficial ownership limit from 4.99% to 9.99%","bullets":["Filed Amended and Restated Certificate of Designation for Series C Non-Voting Convertible Preferred Stock.","Beneficial ownership limitation increased to 9.99% from 4.99%.","Amendment approved by majority of Series C holders and Board of Directors.","No new securities issued; only scrivener's errors corrected.","Effective July 16, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-084617","json":"https://secwatch.observer/filing/0001104659-26-084617.json","markdown":"https://secwatch.observer/filing/0001104659-26-084617.md","text":"https://secwatch.observer/filing/0001104659-26-084617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926084617/0001104659-26-084617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926084617/tm2620727d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-17T20:06:05.300666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}